Advertisement

Certain Genetic Mutations May Increase Risk of Death From Infection in Patients With CLL


Advertisement
Get Permission

Death from infection—the leading cause of death for patients with chronic lymphocytic leukemia (CLL)—may be linked to specific gene mutations, according to results from a study published by Else et al in the journal Leukemia. Testing for these mutations could be used to identify patients at a higher risk of dying from infection and inform disease management strategies.

The study, led by scientists at The Institute of Cancer Research (ICR), London, found that patients with CLL who carried one or more mutations in the BRAF, FBXW7, NRAS, or XPO1 genes were more likely to die from contracting an infection than those without.

Infection causes death patients with CLL largely due to the dysregulation and deficiency of their immune system by the disease or by treatment. For example, defective T-cells and B-cells can increase the chances of infection, and immunosuppressive therapies can make patients more susceptible to infectious diseases. This is especially concerning with the emergence of COVID-19, as it presents another possible route to infection.

Study Details

In the new study, researchers from the ICR and the University of Southampton analyzed the causes of death of patients enrolled in the LRF CLL4 trial, which established the benefit of fludarabine in combination with cyclophosphamide compared with conventional chlorambucil therapy.

The trial collected data from 777 patients with CLL from 1999 to 2004, with an average follow-up time of 13 years.

KEY POINTS

  • The new analysis found that of the 600 patients who died of a known cause, 43% died of infection, either as a primary or secondary cause.
  • Of the genes analyzed, mutations in the BRAF, FBXW7, NRAS, and XPO1 genes were significantly associated with death from infection, with 69% of patients carrying one or more of these mutations dying from infection compared to 39% who lacked any of the mutations.

The new analysis found that of the 600 patients who died of a known cause, 43% died of infection, either as a primary or secondary cause. Comparing blood samples from patients who died from infection vs other causes, the team then found that although there were no differences between the two groups in terms of demographics and prognostic markers, such as disease stage, there were several distinct genetic changes specifically linked to those who had died from infection.

Of the genes analyzed, mutations in the BRAF, FBXW7, NRAS, and XPO1 genes were significantly associated with death from infection, with 69% of patients carrying one or more of these mutations dying from infection compared to 39% who lacked any of the mutations.

Monica Else, MSc, Honorary Senior Scientific Officer in the Division of Molecular Pathology at the ICR, and one of the lead authors of the study, said, “Our study found a link between certain gene mutations and deaths from infection in CLL, which could help to inform future treatment strategies for patients with these infections. It also raises the intriguing possibility of a relationship between these genes and the origin of infections in leukemia. If these mutations turn out to be important in the origin of infections, or in the way that CLL develops as a result of its interaction with infections, then it will be very exciting. It is very possible that infections play a role in the way CLL develops and if so, these mutations might be a part of that.”

Daniel Catovsky, MD, DSc, Professor Emeritus at the ICR, and formerly Team Leader in Haemato-Oncology, was the Principal Investigator of the CLL4 trial. He said, “Infections are a common cause of death in CLL, a disease which otherwise patients can live with for many years with relatively few ill effects. Although our trial initially focused, successfully, on answering the question of which is the most effective cancer drug treatment for CLL, the results have now shed new light on the management of infection—a crucial question for patients, and all the more so now in the era of COVID-19.”

Disclosure: For full disclosures of the study authors, visit nature.com.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement



Advertisement